Cell surface and extracellular proteins of potentially probiotic Lactobacillus reuteri as an effective mediator to regulate intestinal epithelial barrier function
- PMID: 33830286
- DOI: 10.1007/s00203-021-02318-2
Cell surface and extracellular proteins of potentially probiotic Lactobacillus reuteri as an effective mediator to regulate intestinal epithelial barrier function
Abstract
The present study aimed to evaluate the potential of cell surface and extracellular proteins in regulation of intestinal epithelial barrier (IEB) function. Eight potentially probiotic L. reuteri strains were evaluated for presence of mapA gene and its expression on co-culturing with the Caco-2 cells. The ability of untreated (Viable), heat-inactivated, 5 M LiCL treated L. reuteri strains as well as their cell-free supernatant (CFS) to modulate expression of IEB function genes (hBD-2, hBD-3, claudin-1 and occludin) was also evaluated. Caco-2 cells were treated with cell surface and extracellular protein extracts and investigated for change in expression of targeted IEB function genes. The results showed that mapA gene is present in all the tested L. reuteri strains and expression of mapA and its receptors (anxA13 and palm) increase significantly on co-culturing of L. reuteri and Caco-2 cells. Also, up-regulated expression of IEB function genes was observed on co-culturing of L. reuteri (viable, heat-inactivated and CFS) and their protein extracts with Caco-2 cells in contrast to down-regulation observed with the pathogenic strain of Salmonella typhi. Therefore, this study concludes that the cell surface and extracellular protein from L. reuteri act as an effective mediator molecules to regulate IEB function.
Keywords: Caco-2 cells; Intestinal epithelial barrier function; L. reuteri; Probiotics; RT-qPCR.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
A mucus adhesion promoting protein, MapA, mediates the adhesion of Lactobacillus reuteri to Caco-2 human intestinal epithelial cells.Biosci Biotechnol Biochem. 2006 Jul;70(7):1622-8. doi: 10.1271/bbb.50688. Biosci Biotechnol Biochem. 2006. PMID: 16861796
-
Selection of Fermentation Supernatant from Probiotic Strains Exhibiting Intestinal Epithelial Barrier Protective Ability and Evaluation of Their Effects on Colitis Mouse and Weaned Piglet Models.Nutrients. 2024 Apr 12;16(8):1138. doi: 10.3390/nu16081138. Nutrients. 2024. PMID: 38674829 Free PMC article.
-
Receptor-like Molecules on Human Intestinal Epithelial Cells Interact with an Adhesion Factor from Lactobacillus reuteri.Biosci Microbiota Food Health. 2012;31(4):93-102. doi: 10.12938/bmfh.31.93. Epub 2012 Oct 25. Biosci Microbiota Food Health. 2012. PMID: 24936355 Free PMC article.
-
Next-Generation Probiotic Therapy to Protect the Intestines From Injury.Front Cell Infect Microbiol. 2022 Jun 28;12:863949. doi: 10.3389/fcimb.2022.863949. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35837474 Free PMC article. Review.
-
Limosilactobacillus reuteri in immunomodulation: molecular mechanisms and potential applications.Front Immunol. 2023 Aug 9;14:1228754. doi: 10.3389/fimmu.2023.1228754. eCollection 2023. Front Immunol. 2023. PMID: 37638038 Free PMC article. Review.
Cited by
-
The role of potential probiotic strains Lactobacillus reuteri in various intestinal diseases: New roles for an old player.Front Microbiol. 2023 Feb 2;14:1095555. doi: 10.3389/fmicb.2023.1095555. eCollection 2023. Front Microbiol. 2023. PMID: 36819028 Free PMC article. Review.
-
Real-world of Limosilactobacillus reuteri in mitigation of acute experimental colitis.J Nanobiotechnology. 2025 Jan 31;23(1):65. doi: 10.1186/s12951-025-03158-8. J Nanobiotechnology. 2025. PMID: 39891249 Free PMC article.
-
Decreased mucosal adhesion of Lactobacillus species in patients with inflammatory bowel disease.Caspian J Intern Med. 2022 Fall;13(4):713-720. doi: 10.22088/cjim.13.4.71. Caspian J Intern Med. 2022. PMID: 36420328 Free PMC article.
-
Direct and indirect effects of pathogenic bacteria on the integrity of intestinal barrier.Therap Adv Gastroenterol. 2023 May 30;16:17562848231176427. doi: 10.1177/17562848231176427. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37274298 Free PMC article. Review.
-
Microbiome-based therapeutics towards healthier aging and longevity.Genome Med. 2025 Jul 1;17(1):75. doi: 10.1186/s13073-025-01493-x. Genome Med. 2025. PMID: 40597414 Free PMC article. Review.
References
-
- Aleljung P, Shen W, Rozalska B, Hellman U, Ljungh A, Wadstrom T (1994) Purification of collagen-binding proteins of Lactobacillus reuteri NCIB 11951. Curr Microbiol 28:231–236. https://doi.org/10.1007/BF01575966 - DOI - PubMed
-
- Antoni L, Nuding S, Wehkamp J, Stange EF (2014) Intestinal barrier in inflammatory bowel disease. World J Gastroenterol 20(5):1165–1179. https://doi.org/10.3748/wjg.v20.i5.1165 - DOI - PubMed - PMC
-
- Berkes J, Viswanathan VK, Savkovic SD, Hecht G (2003) Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 52(3):439–51. https://doi.org/10.1136/gut.52.3.439 - DOI - PubMed - PMC
-
- Casas IA, Dobrogosz WJ (2000) Validation of the probiotic concept: Lactobacillus reuteri confers broad spectrum protection against disease in humans and animals. Microb Ecol Health Dis 12:247–285. https://doi.org/10.1080/08910600050216246-1 - DOI
-
- Chen CN, Sung HW, Liang HF, Chang WH (2002) Feasibility study using a natural compound (reuterin) produced by Lactobacillus reuteri in sterilizing and cross-linking biological tissues. J Biomed Mater Res 61(3):360–369. https://doi.org/10.1002/jbm.10153 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources